- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07697742
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE) (ELIMINATE)
Evacuation of Lobar Intracranial Hemorrhage Using Microsurgical Technique (ELIMINATE): A Prospective Observational Surgical Cohort Study of Feasibility, Safety, and Radiographic Outcomes
연구 개요
상세 설명
The primary objective of ELIMINATE, a prospective, single-centre, observational surgical cohort study, is to determine whether a standardized microsurgical procedure to evacuate spontaneous lobar intracranial hemorrhage (ICH) is feasible, safe and surgically efficacious in achieving a postoperative residual ICH volume <15cc on 24-hour postoperative CT imaging. The secondary objectives include assessment of tool-tissue forces and bleeding, residual ICH volume postoperatively, and determining the recruitment rate for patients with spontaneous lobar ICH.
The primary clinical outcome will be the proportion of enrolled patients achieving residual ICH volume <15cc on postoperative CT scan at 24 hours. Key outcomes are:
Radiographic: percent evacuation; residual volume (continuous + dichotomized). Functional: mRS at 6 months; EQ-5D-5L at 6 months; mortality at 30 and 180 days.
Intraoperative: force metrics; bleeding quantification; operative time; blood loss.
Feasibility: recruitment rate; proportion operated ≤16 hours; completeness of imaging.
Safety: symptomatic rebleeding ≤72h; postoperative deficits; infections; unplanned OR return; 30-day mortality.
A maximum of 27 adult patients will be enrolled.
Inclusion criteria:
- Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion criteria:
- Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
This study consists of one 180-day study period for each subject. Subjects will be hospitalized for care after their lobar ICH and surgical intervention according to the current standard of care. Subjects will undergo phone assessment on Day 180 by a trained assessor.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Michael D HILL, MD
- 전화번호: 403-210-7786
- 이메일: michael.hill@ucalgary.ca
연구 장소
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 2T9
- Foothills Medical Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
• Adults > 18 years
- CT evidence of acute, spontaneous lobar ICH defined as located <1cm from the cortical surface
- ICH volume is >30cc but <80cc as measured by (length x width x height)/2
- GCS 5-14 at presentation
- NIHSS >5
- Surgery deemed to be feasible within 16h of symptom onset
Exclusion Criteria:
• Underlying secondary etiology (AVM, tumor, etc. if known or identifiable acutely)
- Intraventricular extension estimated to involve >50% of the lateral ventricle
- Preoperative disability that will affect outcome as measured by modified Rankin Scale score (mRS>1 at baseline)
- Individuals presenting with GCS <5 at presentation
- Primary basal ganglia hemorrhage with lobar extension
- End-stage organ failure or life expectancy <6 months
- For patients in whom the treating clinical team elects to proceed with surgical evacuation as part of clinical care, a standardized evacuation of the hematoma will be performed using neuronavigation for optimal craniotomy planning, microsurgical technique and SmartForceps System for quantifiable intraoperative data.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Single cohort deisgn
Surgical evacuation of ICH using microsurgical technicque.
|
Microsurgical hematoma evacuation using microscope and neuronavigation
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recruitment rate
기간: Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
Total recruitment will be recorded each month and report as number of patients recruited per calendar month as an average for duration of the study.
The numerator will be the cumulative total number of pateints recruitment and the denominator will be the number of months elapsed since study start.
The demoninator can be a fractional number; the numerator will also be a positive integer.
|
Quarterly from study onset through study completion with the final recruitment rate recorded at the end of study; total time 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Residual hematoma volume
기간: Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
Residual hematoma volume
|
Up to 2 days after enrolment; post-operative core lab assessment of the 18-54 hour follow-up CT brain scan. The Core Lab will measure residual hematoma volume using summative planimetry over the volume of each CT scan slice image.
|
|
modified Rankin Scale Score
기간: at 90 days and 180 days after enrolment.
|
mRS score is an integer scale ranging from 0 to 6 (7 point interval scale).
Lower score are better and the highest score (6) implies death
|
at 90 days and 180 days after enrolment.
|
|
EuroQoL
기간: at 90 days and 180 days after randomization
|
EQ5D-5L is a 5 domain scale, with a 5 point Likert scale for the quesiton in each domain.
It addresses quality of life and the final score (the EQ5D Index) is adjusted by country to local norms using standardized methodology.
Higher index scores inply a higher quality of life.
|
at 90 days and 180 days after randomization
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Forceps forces
기간: Perioperative/peri-procedural
|
Intra-operative forceps forces during microsurgery.
These devices have haptic measurement capability and will reocrd the degree of force each time dissection or cautery are used.
Recording will be conducted during the entire operative procedure.
|
Perioperative/peri-procedural
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- ELIMINATE 4.0
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .